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The body of work covered in this thesis have established that:
HFpEF is highly prevalent, constitutes at least half the global burden 
of heart failure; and carries a prognosis as poor as most cancers. As 
a condition mainly affecting elderly women, its burden is increasing 
to epidemic proportions in aging societies, where it is becoming the 
predominant form of heart failure. Yet in sharp contrast to the wealth of 
effective therapies for heart failure with reduced ejection fraction, there 
is still no proven therapy to improve survival in HFpEF. A chief obstacle 
to therapeutic advancement is the continued lack of understanding 
of underlying pathophysiologic pathways that may be targeted by 
novel therapies. As a result, outcomes in HFpEF have not improved 
for decades and it is now the greatest unmet need in cardiovascular 
medicine (chapters 1& 2).
The pathophysiology of HFpEF goes beyond left ventricular diastolic 
dysfunction, and also involves systolic ventricular-vascular stiffening, 
myocardial contractile dysfunction (in spite of overall preserved 
chamber ejection fraction), pulmonary hypertension with intrinsic 
pulmonary vascular disease, and even non-cardiovascular organ 
system dysfunction such as pulmonary dysfunction. A unifying 
mechanism underlying the myriad manifestation in HFpEF may be 
endothelial dysfunction with resultant microvascular inflammation and 
ischemia, leading to fibrosis and end organ dysfunction in multiple 
body systems (chapter 3).
The unique predisposition of women to HFpEF may be explained 
by exaggerated ventricular-vascular responses to triggers such as 
pressure overload. The important roles of atrial fibrillation and renal 
dysfunction in HFpEF are underscored by the particularly poor 
prognosis among women with HFpEF and these co-existing conditions 
(chapter 4).
Recognition of the heterogeneity of HFpEF and potential mechanisms 
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beyond cardiac diastolic dysfunction is critical for the design of clinical 
trials in HFpEF. Ongoing clinical trials targeting endothelial dysfunction 
and the nitric oxide – cyclic guanylate monophosphate – phosphokinase 
G axis offer hope for improving outcomes in HFpEF (chapter 5).
Perspectives
The knowledge gained from these studies have challenged prior 
concepts, addressed several gaps, and provided novel insights into 
the syndrome of HFpEF. 
Whereas heart failure was traditionally viewed as synonymous 
with pump failure (i.e. reduced ejection fraction or HFrEF), careful 
epidemiologic review (chapter 2) revealed that heart failure occurred 
in the setting of normal pump function with equal frequency. In fact an 
analysis of epidemiologic trends over time showed that the prevalence 
of HFpEF was increasing relative to that of HFrEF. At the same time, 
the survival in HFpEF had not improved over the last decade, in 
sharp contrast to the improvements observed with HFrEF. These data 
reflected the lack of effective therapies in HFpEF, and underscored the 
urgent need for better understanding of key pathophysiologic targets 
in HFpEF.
Several key observations from the epidemiologic studies in chapter 
2 provided the rationale for the in-depth studies in chapters 3 & 4. 
The initial term “diastolic heart failure” was coined to reflect the belief 
that diastolic dysfunction was the underlying mechanism responsible 
for the syndrome. However, asymptomatic diastolic dysfunction was 
found to be highly prevalent even in the absence of heart failure 
among individuals within the general community, and particularly in the 
elderly and those with systemic hypertension (both key risk factors for 
HFpEF). This called for careful studies comparing HFpEF with age- and 
comorbidity- matched controls without HFpEF (chapter 3). Furthermore, 
the prominence of non-cardiac deaths in HFpEF, as well as the striking 
female predisposition to HFpEF (women outnumbering men by 2:1), 
called for assessment of the role of non-cardiac comorbidities in the 
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pathophysiology of HFpEF (chapter 3) and further studies on sex-
specific mechanisms (chapter 4).
We provided the first population-based evidence that, compared to 
age- and sex- matched controls with hypertension but without heart 
failure, more severe diastolic dysfunction was present in HFpEF, 
thus supporting a key role for worsening diastolic dysfunction in 
the progression from asymptomatic hypertensive heart disease to 
HFpEF (Lam Circulation 2007). These cross-sectional findings were 
later supported by longitudinal evidence from the Framingham Heart 
Study showing that asymptomatic diastolic dysfunction preceded and 
predicted the future onset of HFpEF (Lam Circulation 2011). However 
these studies also challenged prior concepts by showing a prominent 
presence of systolic ventricular-vascular stiffening (Lam Circulation 
2007) and occult myocardial contractile dysfunction despite an overall 
preserved ejection fraction (Borlaug, Lam JACC 2009) in HFpEF, and 
establishing that beyond cardiac dysfunction, pulmonary dysfunction 
also predicted the onset of future HFpEF (Lam Circulation 2011). In 
fact, intrinsic pulmonary vascular disease was present in HFpEF, and 
pulmonary hypertension was a potent independent predictor of survival, 
indicating its pathophysiologic role in HFpEF progression (Lam JACC 
2009). This opened the door to therapeutic approaches targeting 
pulmonary arterial hypertension in HFpEF (e.g. phosphodiesterase-5 
inhibitors). 
Further insights were provided by studying sex differences in HFpEF 
(chapter 4). The importance of left ventricular remodeling response 
to a common trigger (pressure overload) was demonstrated in these 
studies, where women displayed more concentric cardiac remodeling 
compared to men with HFpEF (Gori, Lam Eur J Heart Fail 2014). 
Additionally, atrial fibrillation and renal dysfunction were shown to be 
key drivers of poor outcomes in HFpEF, particularly among women (Circ 
Heart Fail 2012). Ongoing studies are now addressing these 2 factors 
in remaining questions such as cause versus effect and interaction with 
age and sex in the pathogenesis and progression of HFpEF. Answers 
to these important questions will inform future clinical trial design and 
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the potential to treat HFpEF by treating its comorbidities (chapter 5).
Tying things together around a unifying concept, a central role of 
endothelial dysfunction, microvascular inflammation and the nitric 
oxide – cyclic guanylate monophosphate – phosphokinase G axis has 
emerged (Lam JACC 2012, Paulus and Tschöpe JACC 2013). This 
paradigm shift carries great clinical significance in that: (1) HFpEF 
is viewed as a systemic disease (rather than isolated left ventricular 
diastolic dysfunction); (2) the important role of comorbidities is 
acknowledged; (3) novel therapeutic approaches targeting this axis 
(e.g. soluble guanylate cyclase stimulators) have now surfaced and 
are being tested in ongoing clinical trials (chapter 5). 
Conclusions
Much progress has been made over the last decade in the recognition 
and understanding of HFpEF: from questioning its existence to 
acknowledgement of its prominence as one of the greatest unmet 
needs in cardiology today; from viewing it as pure “diastolic heart 
failure” to an understanding of the myriad non-diastolic and even non-
cardiac mechanisms that contribute to its pathophysiology; and from 
blindly extrapolating therapies from HFrEF to the development of novel 
approaches targeted at key underlying pathways.
Yet our work is far from done. We have yet to achieve improvements 
in outcomes in randomized controlled clinical trials for HFpEF, and 
international guidelines for HFpEF have remained unchanged for 
decades. Ongoing trials offer hope. Future research into endothelial-
myocyte cross-talk, microvascular ischemia and microvascular 
inflammation may provide further therapeutic targets (Lim, Lam Eur 
Heart J. 2015 Apr 23. pii: ehv132. [Epub ahead of print]).
